GlaxoSmithKline and Sanofi single Covid booster trial shows good immune response
A Covid-19 vaccine candidate being developed by GlaxoSmithKline and Sanofi delivers a strong immune response, preliminary trial results have shown. The companies said the study of the vaccine as a single booster dose showed an increase in neutralising antibodies, regardless of the primary vaccine received such as Pfizer-BioNTech or AstraZeneca, and for all age groups tested.
